RBC Bioscience Corporation (6848.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$20.80 (+0.00%) as of
Key statistics
- P/E (TTM)
- 14.15
- EPS (TTM)
- 1.47
- Dividend yield
- 22.65%
- 52-week range
- 14.30 – 28.15
- Beta
- 0.47
- Revenue (TTM)
- 220.6M
- Profit margin
- 9.55%
- Volume
- 11.81k
About RBC Bioscience Corporation
RBC Bioscience Corporation manufactures and sells reagents and devices for life science and molecular diagnosis. It offers robotic bench-top workstation for nucleic acid purification under the MagCore Plus II and Giga Automated Nucleic Acid Extractor names; MagCore Super Automated Nucleic Acid Extractor, an automated workstation for nucleic acid extraction; and MagCore EDA Automatic Extraction and Smart PCR Setup, an instrument for nucleic acid extraction and PCR setup pre-treatment. The company also provides NGS, genomic DNA, viral nucleic acids, and total RNA kits. It has operations in Taiwan, rest of Asia, Africa, the United States, and internationally. RBC Bioscience Corporation was founded in 1995 and is based in New Taipei City, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- New Taipei City, Taiwan
- Employees
- 50
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.